Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Wolf

Showing results (751-760 of 810) with videos related to

Pageof 81
Sort By:
Molecular Psychiatry|February 7, 2024
Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomicsM D Hill, S S Gill, H Le-Niculescu, et al.
Gynecologic Oncology|March 7, 2009
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancerKathleen M Schmeler, Saroj Vadhan-Raj, Pedro T Ramirez, et al.
The Journal of Heart Transplantation|January 1, 1989
Efficacy and safety of constant-rate intravenous cyclosporine infusion immediately after heart transplantationT J Schroeder, S A Myre, D B Melvin, et al.
Infection and Immunity|November 22, 2005
Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteersNadav Orr, David E Katz, Jacob Atsmon, et al.
Cancer Research|March 5, 2003
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancerJanos L Tanyi, Andrew J Morris, Judith K Wolf, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 16, 2009
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomasCelestine S Tung, Samuel C Mok, Yvonne T M Tsang, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 14, 2017
miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture ModelMerrie Mosedale, J Scott Eaddy, O Joseph Trask, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2020
Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency VirusJennifer R Zelnick, Amrita Daftary, Christina Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trialDavid Cella, Roy S Herbst, Thomas J Lynch, et al.
Elife|May 26, 2022
Binary outcomes of enhancer activity underlie stable random monoallelic expressionDjem U Kissiov, Alexander Ethell, Sean Chen, et al.
Pageof 81

Showing results (751-760 of 810) with videos related to

Sort By:
Pageof 81
Molecular Psychiatry|February 7, 2024
Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomicsM D Hill, S S Gill, H Le-Niculescu, et al.
Gynecologic Oncology|March 7, 2009
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancerKathleen M Schmeler, Saroj Vadhan-Raj, Pedro T Ramirez, et al.
The Journal of Heart Transplantation|January 1, 1989
Efficacy and safety of constant-rate intravenous cyclosporine infusion immediately after heart transplantationT J Schroeder, S A Myre, D B Melvin, et al.
Infection and Immunity|November 22, 2005
Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteersNadav Orr, David E Katz, Jacob Atsmon, et al.
Cancer Research|March 5, 2003
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancerJanos L Tanyi, Andrew J Morris, Judith K Wolf, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 16, 2009
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomasCelestine S Tung, Samuel C Mok, Yvonne T M Tsang, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 14, 2017
miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture ModelMerrie Mosedale, J Scott Eaddy, O Joseph Trask, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2020
Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency VirusJennifer R Zelnick, Amrita Daftary, Christina Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trialDavid Cella, Roy S Herbst, Thomas J Lynch, et al.
Elife|May 26, 2022
Binary outcomes of enhancer activity underlie stable random monoallelic expressionDjem U Kissiov, Alexander Ethell, Sean Chen, et al.
Pageof 81